ACUR insider filings
ACURA PHARMACEUTICALS, INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-01-15. Screen ACUR transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ACUR between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ACURA PHARMACEUTICALS, INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-15 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2026-01-15 | 4 | ROSS GEORGE K — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2026-01-15 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-02-04 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-01-24 | 4 | ROSS GEORGE K — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-01-24 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-01-02 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-01-02 | 4 | ROSS GEORGE K — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-01-02 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2024-01-02 | 4 | WESSON BRUCE F — Director | Option exercise (M): 37,500 · Option exercise (M): 37,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) | EDGAR |
| 2023-11-20 | 4 | Brzeczko Albert W — See Remarks | Option exercise (M): 40,000 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2023-11-20 | 4 | Jones Robert B — President & CEO | Option exercise (M): 40,000 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2023-11-20 | 4 | Seiser Robert A — VP, Treasurer & Controller | Option exercise (M): 40,000 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2023-11-20 | 4 | CLEMENS PETER A — Senior VP & CFO | Option exercise (M): 40,000 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | Brzeczko Albert W — See Remark | Option exercise (M): 34,000 · Option exercise (M): 34,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | Jones Robert B — President & CEO | Option exercise (M): 50,000 · Option exercise (M): 50,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | Seiser Robert A — VP, Treasurer & Controller | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | ROSS GEORGE K — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | WESSON BRUCE F — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2023-01-05 | 4 | CLEMENS PETER A — Senior VP & CFO | Option exercise (M): 40,000 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2022-08-05 | 4 | Brzeczko Albert W — VP, Pharma Sciences - APT | Option exercise (M): 43,333 · Option exercise (M): 9,333 (derivative) · Option exercise (M): 34,000 (derivative) | EDGAR |
| 2022-08-05 | 4 | Jones Robert B — President & CEO | Option exercise (M): 63,666 · Option exercise (M): 13,666 (derivative) · Option exercise (M): 50,000 (derivative) | EDGAR |
| 2022-08-05 | 4 | Seiser Robert A — VP, Controller & Treasurer | Option exercise (M): 24,666 · Option exercise (M): 4,666 (derivative) · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2022-08-05 | 4 | CLEMENS PETER A — Senior VP & CFO | Option exercise (M): 49,333 · Option exercise (M): 9,333 (derivative) · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2022-03-18 | 4 | Brzeczko Albert W — VP, Pharma Sciences - APT | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2022-03-18 | 4 | Jones Robert B — President & CEO | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2022-03-18 | 4 | Seiser Robert A — VP, Controller & Treasurer | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2022-03-18 | 4 | CLEMENS PETER A — Senior VP & CFO | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2022-01-12 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2022-01-11 | 4 | WESSON BRUCE F — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2022-01-10 | 4 | ROSS GEORGE K — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2022-01-05 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 66,666 · Option exercise (M): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2021-06-28 | 4 | Abuse Deterrent Pharma, LLC — 10% owner | Conversion (C): 42,984,375 @ $0.16 · Conversion (C): 6,877,500 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Schutte John — 10% owner | Conversion (C): 42,984,375 @ $0.16 · Conversion (C) @ $0 | EDGAR |
| 2021-05-28 | 4 | THANGARAJ IMMANUEL — Director | Grant/award (A): 66,666 (derivative) | EDGAR |
| 2021-05-28 | 4 | ROSS GEORGE K — Director | Grant/award (A): 66,666 (derivative) | EDGAR |
| 2021-05-28 | 4 | SKELLY WILLIAM G — Director | Grant/award (A): 66,666 (derivative) | EDGAR |
| 2021-05-28 | 4 | WESSON BRUCE F — Director | Grant/award (A): 66,666 (derivative) | EDGAR |
| 2021-02-26 | 4 | Seiser Robert A — VP, Treasurer & Controller | Option exercise (M): 20,000 @ $0.15 · Tax withholding (F): 7,550 @ $0.40 · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2021-02-26 | 4 | EMIGH JAMES F — VP, Corporate Development | Option exercise (M): 20,000 @ $0.15 · Tax withholding (F): 7,550 @ $0.40 · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2021-02-26 | 4 | CLEMENS PETER A — Senior VP & CFO | Option exercise (M): 40,000 @ $0.15 · Tax withholding (F): 15,100 @ $0.40 · Option exercise (M): 40,000 (derivative) | EDGAR |
| 2021-01-12 | 4 | THANGARAJ IMMANUEL — Director | Option exercise (M): 54,790 · Option exercise (M): 54,790 (derivative) | EDGAR |
| 2021-01-06 | 4 | Seiser Robert A — VP, Treasurer & Controller | Option exercise (M): 24,667 · Tax withholding (F): 10,686 @ $0.21 · Option exercise (M): 4,667 (derivative) · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2021-01-06 | 4 | EMIGH JAMES F — VP, Corporate Development | Option exercise (M): 24,667 · Tax withholding (F): 7,402 @ $0.21 · Option exercise (M): 4,667 (derivative) · Option exercise (M): 20,000 (derivative) | EDGAR |
| 2021-01-06 | 4 | ROSS GEORGE K — Director | Option exercise (M): 54,790 · Option exercise (M): 54,790 (derivative) | EDGAR |
| 2021-01-06 | 4 | SKELLY WILLIAM G — Director | Option exercise (M): 54,790 · Option exercise (M): 54,790 (derivative) | EDGAR |
| 2021-01-06 | 4 | WESSON BRUCE F — Director | Option exercise (M): 54,790 · Option exercise (M): 54,790 (derivative) | EDGAR |
| 2021-01-06 | 4 | CLEMENS PETER A — Senior VP & CFO | Option exercise (M): 49,334 · Tax withholding (F): 19,514 @ $0.21 · Option exercise (M): 9,334 (derivative) · Option exercise (M): 40,000 (derivative) | EDGAR |
Recent 8-K events — ACURA PHARMACEUTICALS, INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACUR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs